<DOC>
	<DOCNO>NCT00686179</DOCNO>
	<brief_summary>The purpose study evaluate effect cardiac repolarisation supratherapeutic dos AZD3480 compare placebo healthy male volunteer , subgrouped extensive metabolisers poor metabolisers accord CYP2D6 metabolic capacity , use moxifloxacin positive control .</brief_summary>
	<brief_title>Investigate Effect QT/QTc Interval Repeated Escalating Doses AZD3480 During 6 Days</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Participation previous study genotyping identification extensive poor metaboliser ( CYP2D6 enzyme ) Physically mentally healthy male volunteer History clinically significant disease illness . Participation another study last 3 month Prescribed nonprescribed medication 3 week prior first treatment day followup except paracetamol ( max 1.5 g per day . )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>TQT</keyword>
	<keyword>ECG</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
	<keyword>AZD3480</keyword>
	<keyword>ECG ( QTc effect )</keyword>
</DOC>